Neuphoria Therapeutics Inc. (NEUP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Neuphoria Therapeutics Inc. (NEUP) closed at USD 3.24 on 2026-10-14, a change of -31.2 % over the past year, with a market capitalization of USD 17.91M.

Neuphoria Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Neuphoria Therapeutics Inc. key figures

Previous close

USD 3.24 (2026-10-14)

1-year change

-31.2 %

Market cap

USD 17.91M

Enterprise value

USD -1.92M

P/E ratio (trailing)

-1.09

P/E ratio (forward)

-1.35

EPS (trailing)

-3.03

EPS (forward)

-2.46

PEG ratio

n/a

Price to book

0.73

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.11

Employees

1

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Neuphoria Therapeutics Inc. and compare it with other stocks.